CD38 and cancer: A recent study by Verma et al. highlights some of the challenges of trying to combine ICB with cancer vaccines.4 The investigators demonstrated that PD1 blockade of suboptimally primed CD8+ T cells (as typically seen in cancers) results in dysfunctional T cells characterized by upregulation of CD38, and the inability to respond to subsequent antigen or vaccine stimulation.